View More View Less
  • 1 Department of Rehabilitation, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $752.00

Abstract

In this study, the ability of microRNA-1906 (miR-1906) to attenuate bone loss in osteoporosis was evaluated by measuring the effects of a miR-1906 mimic and inhibitor on the cellular toxicity and cell viability of MC3T3‐E1 cells. Bone marrow-derived macrophage (BMM) cells were isolated from female mice, and tartrate-resistant acid phosphatase signalling was performed in miR-1906 mimic-treated, receptor-activated nuclear factor kappa-B (NF-κB) ligand (RANKL)-induced osteoclasts. In-vivo, osteoporosis was induced by ovariectomy (OVX). Rats were treated with 500 nmol/kg of the miR-1906 mimic via intrathecal administration for 10 consecutive days following surgery. The effect of the miR-1906 mimic on bone mineral density (BMD) in OVX rats was observed in the whole body, lumbar vertebrae and femur. Levels of biochemical parameters and cytokines in the serum of miR-1906 mimic-treated OVX rats were analysed. The mRNA expression of toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), p-38 and NF-κB in tibias of osteoporotic rats (induced by ovariectomy) was observed using quantitative reverse-transcription polymerase chain reaction. Treatment with the miR-1906 mimic reduced cellular toxicity and enhanced the cell viability of MC3T3‐E1 cells. Furthermore, osteoclastogenesis in miR-1906 mimic-treated, RANKL-induced osteoclast cells was reduced, whereas the BMD in the miR-1906 mimic-treated group was higher than in the OVX group of rats. Treatment with the miR-1906 mimic also increased levels of biochemical parameters and cytokines in the serum of ovariectomised rats. Finally, mRNA expression levels of TLR4, MyD88, p-38 and NF-κB were lower in the tibias of miR-1906 mimic-treated rats than in those of OVX rats. In conclusion, the miR-1906 mimic reduces bone loss in rats with ovariectomy-induced osteoporosis by regulating the TLR4/MyD88/NF‐κB pathway.

  • 1.

    Office of the Surgeon General (US). Bone health and osteoporosis: a report of the Surgeon General. Rockville (MD): Office of the Surgeon General (US); 2004.

    • Search Google Scholar
    • Export Citation
  • 2.

    Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000; 106: 12031204.

  • 3.

    Ji M-X, Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med 2015; 1: 913.

  • 4.

    Zhao R. Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective. Int J Med Sci 2012; 9: 825832.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab 2012; 23: 576581.

  • 6.

    Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol 2011; 6: 121145.

  • 7.

    Alonso-Pérez A, Franco-Trepat E, Guillán-Fresco M, Jorge-Mora A, López V, Pino J, . Role of toll-like receptor 4 on osteoblast metabolism and function. Front Physiol 2018; 9: 504.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Geng Q, Gao H, Yang R, Guo K, Miao D. Pyrroloquinoline quinone prevents estrogen deficiency-Induced osteoporosis by inhibiting oxidative stress and osteocyte senescence. Int J Biol Sci 2019; 15: 5868.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Fröhlich L. MicroRNAs at the interface between osteogenesis and angiogenesis as targets for bone regeneration. Cells 2019; 8: 121.

  • 10.

    Fang X, Zhou H, Huang S, Liu J. MiR-1906 attenuates neuropathic pain in rats by regulating the TLR4/mTOR/Akt signaling pathway. Transl Neurosci 2019; 10: 175179.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Xu X, Wen Z, Zhao N, Xu X, Wang F, Gao J, . MicroRNA-1906, a novel regulator of toll-like receptor 4, ameliorates ischemic injury after experimental stroke in mice. J Neurosci 2017; 37: 1049810515.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Kim JL, Moon CW, Son YS, Kim SJ. Combined effect of bilateral ovariectomy and anterior cruciate ligament transection with medial meniscectomy on the development of osteoarthritis model. Ann Rehabil Med 2016; 40: 583.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2014; 142: 155170.

  • 14.

    Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res 2013; 92: 860867.

  • 15.

    Paul T, Shetty S, Kapoor N, Bondu J, Thomas N. Bone turnover markers: Emerging tool in the management of osteoporosis. Indian J Endocrinol Metab 2016; 20: 846.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Weitzmann MN. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006; 116: 11861194.

  • 17.

    Mouihate A. TLR4-mediated brain inflammation halts neurogenesis: impact of hormonal replacement therapy. Front Cell Neurosci 2014; 8.

  • 18.

    Sato N, Takahashi N, Suda K, Nakamura M, Yamaki M, Ninomiya T, . MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. J Exp Med 2004; 200: 601611.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Putnam NE, Fulbright LE, Curry JM, Ford CA, Petronglo JR, Hendrix AS, . MyD88 and IL-1R signaling drive antibacterial immunity and osteoclast-driven bone loss during Staphylococcus aureus osteomyelitis. PLoS Pathog 2019; 15: e1007744.

    • Crossref
    • Search Google Scholar
    • Export Citation

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Nov 2020 0 0 0
Dec 2020 0 0 0
Jan 2021 28 3 3
Feb 2021 161 4 8
Mar 2021 183 10 9
Apr 2021 163 3 3
May 2021 0 0 0